Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Observational Study of LUMRYZ in Narcolepsy
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Avadel
- Target Recruit Count
- 75
- Registration Number
- NCT06792708
- Locations
- 🇺🇸
Jeremy D McConnell, MD PA, Bradenton, Florida, United States
🇺🇸Comprehensive Sleep Center, East Lansing, Michigan, United States
🇺🇸Patient First MD, Middletown, New Jersey, United States
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Avadel
- Target Recruit Count
- 150
- Registration Number
- NCT06525077
- Locations
- 🇺🇸
Alpine Clinical Research Center, Boulder, Colorado, United States
🇺🇸Florida Pediatric Institute, Winter Park, Florida, United States
🇺🇸Clinical Research Institute, Stockbridge, Georgia, United States
An Open Label Study of FT218 in Subjects With Narcolepsy
- Conditions
- Excessive Daytime SomnolenceSleep DisturbanceSleep Wake DisordersCataplexySleep DisorderNarcolepsy
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Avadel
- Target Recruit Count
- 184
- Registration Number
- NCT04451668
- Locations
- 🇺🇸
Sleep Disorders Center of Alabama, Birmingham, Alabama, United States
🇺🇸Stanford Sleep Medicine, Redwood City, California, United States
🇺🇸SDS Clinical Trials, Santa Ana, California, United States
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
- Conditions
- NarcolepsyExcessive Daytime SleepinessCataplexy
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Avadel
- Target Recruit Count
- 212
- Registration Number
- NCT02720744
- Locations
- 🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸University Sleep Disorder Center, Auburn, Alabama, United States
🇺🇸Sleep Disorders Center of Alabama, Birmingham, Alabama, United States
News
Court Upholds FDA's Approval of Avadel's Lumryz Over Jazz's Xywav in Orphan Drug Exclusivity Dispute
A U.S. District Court upheld the FDA's decision to approve Avadel's Lumryz, a once-nightly sodium oxybate formulation, for narcolepsy.